Background: There is lack of consensus if hepatitis B virus (HBV) DNA can be regarded as a surrogate marker of liver damages in patients with chronic hepatitis B (CHB).
INTRODUCTION
HBV, a member of the family Hepadnaviridae, is a noncytopathic DNA virus. About 2 billion people have been infected globally at some point in their lives with HBV, and approximately 350 to 400 million people are chronically infected with this virus. Epidemiologic data indicate that HBV accounts for 0.5 to 1.2 million deaths annually, and approximately 15 to 25% of chronic hepatitis B patients will eventually die of HBV-related liver disease. 1, 2 Chronic HBV-infected subjects express different virological, biochemical, immunological and histological markers; some of which are detectable in the sera; whereas, others can be assessed in liver biopsy specimens. HBV DNA, HBsAg, HBeAg and ALT are detected in the sera for diagnosis of HBV infection and to assess extent of liver damages in patients with CHB. However, liver biopsy provides most critical evidences of liver injury. It is a matter of controversy whether HBV DNA may be used as surrogate marker of liver damages in CHB patients. Some investigators have shown that HBV DNA levels may be useful in this context. [3] [4] [5] [6] [7] [8] However, data contrary to this conception also exist and it seems that serum HBV DNA may not reflect the extent of liver damages in CHB patients. [9] [10] [11] [12] Bangladesh, a South Asian country with 160 million people, exhibits an intermediate prevalence for HBV infection. The lifetime risk of acquiring this infection in Bangladesh is >40%. It has been shown that this virus is responsible for about 10 to 35% cases of acute viral hepatitis, about 35% cases of fulminant hepatic failure, about 33 to 40% cases of chronic hepatitis and 46% cases of hepatocellular carcinoma. 13 The apparent discrepancies about usefulness of HBV DNA in determining extent of liver damages may be due to differences of study population and other explored factors. However, this has tremendously comprised both proper diagnosis and effective management of CHB patients in most developing countries. This present study in which HBV DNA and HBeAg were compared with findings of liver biopsy in 77 consecutive patients with CHB in Bangladesh provided information about complexity of HBV management at Bangladesh.
MATERIALS AND METHODS
Patients with chronic HBV infection (HBsAg-positive for at least 6 months) attending Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh between March 2008 and December 2008 were enrolled in this study. Written informed consent was obtained from each patient. The patients were positive for serum HBV DNA and negative for antihepatitis C virus antibody.
Serum ALT levels and prothrombin time were assessed commercially. The cutoff value for abnormal ALT was 42 U/L. HBeAg was checked commercially by ELISA using a commercial kit (Abbott Labs, Chicago, IL, USA). Serum HBV DNA was quantified in a polymerase chain reaction method using a commercial kit (Amplicon HBV Monitor Assay, RT-PCR, Roche Molecular Systems, CA, USA). The lower limit of detection was 500 copies of HBV DNA/ml. A percutaneous liver biopsy was performed with written consent of the patients. Biopsies were performed under local anesthesia using a 16G Tru-cut biopsy needle (Cardinal Health, McGaw Park, IL, USA). A biopsy specimen of more than 1.0 cm in length with five to six portal tracts was accepted when examined microscopically. Histology was graded according to the histologic activity index (HAI) using the criteria of Knodell et al. 14 The total HAI score comprises necroinflammation (HAI-N1) and fibrosis (HAI-F) scores. The HAI-N1 scale includes three components (0-10, piecemeal necrosis; 0-4, lobular necrosis and inflammation; 0-4, portal inflammation). Minimal hepatitis, mild hepatitis, and moderate hepatitis were regarded when HAI-N1 score was 0-4, 5-8 and 9-12 respectively. HAI-F was graded according to severity: 0, absence of fibrosis; 1, fibrous portal expansion; 3, bridging fibrosis; 4, cirrhosis.
RESULTS
A total of 77 patients were enrolled in the study to assess the relationship of HBV DNA and HBeAg with extent of liver damages or hepatitis. HBV DNA and HBeAg were assessed in the sera and extent of hepatitis was evaluated by liver biopsy. On the basis of levels of HBV DNA in the sera, the patients were divided in two groups: (1) high HBV DNA; patients expressing HBV DNA of >10 5 copies/ml, and (2) low HBV DNA; patients with HBV DNA of <10 5 copies/ml in the sera.
Twenty-nine out of 77 patients were HBeAg-positive and the rest 48 were HBeAg-negative. Out of 29 HBeAgpositive patients, 27 (93%) had high levels of HBV DNA, whereas only 2 (7%) had low levels of HBV DNA in the sera. However, levels of HBV DNA showed a different picture in HBeAg-negative patients. Out of 48 HBeAgnegative patients, HBV DNA levels were >10 5 copies/ml in 8 patients, whereas the rest 40 patients of this group had low HBV DNA. Taken together, 35 patients had high HBV DNA, whereas 42 patients had low HBV DNA in the sera in this cohort.
The main purpose of this study was to assess if there is a relation between serum HBV DNA or HBeAg with extent of hepatitis or hepatic fibrosis in liver biopsy. As described in the Method section, the extent of hepatic inflammation and liver fibrosis was graded according to the criteria of Knodell et al. When the necrosis score was HAI-N1 0-4, the patients were regarded to have minimal hepatitis. On the contrary, if the levels of hepatic inflammation were HAI-N1 5-8 and HAI-N1 9-12, they were regarded as having mild and moderate hepatitis, respectively. A total of 36, 34 and seven patients had minimal, mild and moderate hepatitis (Table 1) .
Next, we assessed if the levels of HBV DNA reflect the levels of liver injury in CHB patients. As shown in Table 2 , out of 35 patients with high HBV DNA, only 5 had moderate levels of hepatitis. The levels of hepatitis were minimal or mild in rest 30 patients with high levels of HBV DNA. Moderate levels of hepatitis were detected in two out of 42 patients with low HBV DNA.
The relation between HBeAg expression and extent of hepatitis has been shown in Table 3 . Mild hepatitis was equally distributed between HBeAg-positive and HBeAgnegative patients in this cohort. Moderate hepatitis was seen in higher ratio in HBeAg-negative patients (5 of 48, 10.4%) than in HBeAg-positive patients (2 of 29, 6.9%). 
EJOHG
The extents of hepatic fibrosis were mild in most HBeAgpositive patients with CHB irrespective of their HBV DNA levels. In 24 of 27 HBeAg-positive patients with high HBV DNA, had minimal to mild fibrosis (HAI-F 0-1). Also, two HBeAg-positive patients with low HBV DNA have minimal to mild fibrosis (HAI-F 0-1). However, in HBeAg-negative patients, four of eight patients with high HBV DNA had bridging fibrosis (HAI-F 3) and the rest four patients had mild hepatic fibrosis. In HBeAg-negative patients with low HBV (Table 4 ). The extents of hepatitis and hepatic fibrosis in two HBeAg-positive CHB patients and three HBeAg-negative patients were shown in Figures 1A and B and Figures 2A to C. It seems that liver histology was independent of the HBeAg expression or levels of ALT or HBV DNA concentrations.
DISCUSSION
The aim of this study was to assess whether HBV DNA may be used as a surrogate marker of liver damages in CHB patients of Bangladesh. Some investigators have reported about the utility of HBV DNA in assessing liver damages. [2] [3] [4] [5] [6] [7] [8] Also, a role of serum HBV DNA has been shown as a marker of prognosis of antiviral therapy in CHB patients. [15] [16] [17] [18] [19] As Bangladesh harbors about 8 to 10 million chronic HBV infected subjects, we studied if serum HBV DNA levels can be used to assess the extent of liver damages in CHB patients from Bangladesh. The present study provided mixed signals about the significance of serum HBV DNA in CHB patients. In HBeAg-positive patients, the high levels of serum HBV DNA were not related with increased levels of liver damages. This was seen in the context of both liver inflammation and hepatic fibrosis. However, in patients with HBeAg-negative CHB, some patients with high HBV DNA also had comparatively higher levels of liver damages. Taken together, it does not appear that HBV DNA or HBeAg reflect proper surrogate marker of liver damages in CHB patients of Bangladesh.
The study presented here contradicted what that have been reported by other investigators about the impact of serum HBV DNA for determining extent of liver damages in CHB patients. [2] [3] [4] [5] [6] [7] [8] But, this study has apparently supported several studies about little impact of HBV DNA from developing countries. [9] [10] [11] [12] In fact, studies from Bangladesh and India along with other countries have already shown that patients with very low levels of HBV DNA also exhibit considerable levels of liver damages. Al-Mahtab et al have shown that considerable numbers of HBeAg-negative patients with <10,000 copies/ml of HBV DNA, and normal ALT had severe liver inflammation and hepatic fibrosis. 20 However, there are several limitations of this study and the outcomes should be cautiously analyzed to develop insights about HBV pathogenesis. We have enrolled few patients in this study, which may not be enough to draw a firm conclusion. The next, we took liver biopsies for once only that may not be sufficient to assay the kinetics of hepatic damages of these patients. In addition, HBV DNA was measured once. In fact, this preliminary study indicates that a controlled study with considerable numbers of patients should be conducted in future.
In fact, management of CHB patients is a critical factor in developing countries including Bangladesh. [21] [22] [23] Lacks of proper surrogate markers of antiviral therapy make the management of CHB patients difficult. Taken together, it appears that pathogenesis of CHB is a complex issue and dependence of HBV markers should be cautiously planned for developing insights about HBV pathogenesis and management of CHB patients.
